KALA BIO (KALA) Q4 2025 earnings summary

Executive summary

• Transitioned from biopharmaceutical R&D to focus on developing an AI infrastructure platform for the biotech industry after discontinuing KPI-012 and MSC-S platform due to failed clinical trial endpoints.

• Entered an exclusive license for the Researgency AI research platform in March 2026, aiming to provide on-premises AI solutions for biotech and pharma clients.

• Monetization of legacy biologics assets and strategic partnerships remain a parallel priority.

Financial highlights

• Net loss for 2025 was $26.98 million, an improvement from $38.51 million in 2024.

• Operating expenses decreased to $39.16 million in 2025 from $40.98 million in 2024, driven by lower R&D costs after clinical program discontinuation.

• Cash and cash equivalents at year-end 2025 were $7.6 million, down from $51.2 million at year-end 2024.

• Accumulated deficit as of December 31, 2025 was $694.9 million.

• No revenue-generating commercial products; grant income from CIRM Award ceased after clinical program halt.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2027, with additional financing and asset monetization under evaluation.

• No near-term revenue expected from AI platform or biologics assets; profitability not anticipated in the foreseeable future.

• Strategic focus on AI platform development, customer acquisition, and potential partnerships.